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C E L L  B I O L O G Y
Mitochondria form contact sites with the nucleus 
to couple prosurvival retrograde response
Radha Desai1*†, Daniel A. East1*, Liana Hardy1‡, Danilo Faccenda1, Manuel Rigon1, 
James Crosby1, María Soledad Alvarez1§, Aarti Singh1, Marta Mainenti1||, Laura Kuhlman Hussey1, 
Robert Bentham2, Gyorgy Szabadkai2,3,4, Valentina Zappulli5, Gurtej K. Dhoot1, Lisa E. Romano6, 
Dong Xia1, Isabelle Coppens7, Anne Hamacher-Brady7, J. Paul Chapple6, Rosella Abeti8,  
Roland A. Fleck9, Gema Vizcay-Barrena9, Kenneth Smith10, Michelangelo Campanella1,2¶
Mitochondria drive cellular adaptation to stress by retro-communicating with the nucleus. This process is known as 
mitochondrial retrograde response (MRR) and is induced by mitochondrial dysfunction. MRR results in the nuclear 
stabilization of prosurvival transcription factors such as the nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-B). Here, we demonstrate that MRR is facilitated by contact sites between mitochondria and the 
nucleus. The translocator protein (TSPO) by preventing the mitophagy-mediated segregation o mitochonria is 
required for this interaction. The complex formed by TSPO with the protein kinase A (PKA), via the A-kinase an-
choring protein acyl-CoA binding domain containing 3 (ACBD3), established the tethering. The latter allows for cho-
lesterol redistribution of cholesterol in the nucleus to sustain the prosurvival response by blocking NF-B deacetyla-
tion. This work proposes a previously unidentified paradigm in MRR: the formation of contact sites between 
mitochondria and nucleus to aid communication.
INTRODUCTION
Mitochondria actively participate in the reprogramming of mammalian 
cells (1, 2). In response to endogenous or exogenous perturbations, 
they retro-communicate with the nucleus to drive the transcription 
of genes. This pathway of signaling is known as the mitochondrial 
retrograde response (MRR) and is exploited in the pathogenesis of 
uncontrolled cellular proliferation (3). In cancer, prosurvival transcrip-
tion factors (TFs) like the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-B) (4–7) are stabilized by the hyperpro-
duction of reactive oxygen species (ROS) generated from dysfunctional 
mitochondria. Impaired cell signaling and nuclear accumulation of 
NF-B are the acknowledged readouts of active MRR in mammals 
(8, 9). In these species, the lack of homology with the yeast Rtg1/Rtg2/
Rtg3 system (10) entails the engagement of a more complex framework 
of regulators and executors (11) when mitochondria communicate 
with the nucleus. In keeping with this, the recent identification of 
MRR molecules (8, 9) failed to explain the interplay between mito-
chondria and nucleus during stress. Aspects intimately involved in 
the organelle physiopathology such as (i) dynamic remodeling (ii) and 
trafficking of lipids had been unexplored, and for these, we postu-
lated a catalytic role in the MRR signaling. Abnormalities in lipid 
metabolism are distinctive features of cancer cells, which vastly rely 
on MRR (12), and in these, the increased mitochondrial network size 
following the stabilization of profusion proteins (e.g., OPA-1, Mnf1, 
2, ATPIF1) (13–15) mediates cytoprotective resistance to organelle 
disassembly. Enlarged mitochondria by occupying the surrounding 
cytosolic space would therefore hold a greater chance of establish-
ing proximity events with other organelles to generate hotspots of 
communication. It is well established that hyperfused, remodeled 
mitochondria interact with the endoplasmic reticulum (ER), while 
unexplored is whether they could become physically coupled with 
the nucleus to expedite the execution of MRR.
To test the hypothesis of domains of communication between 
mitochondria and nucleus during MRR, we traced the molecular 
physiology of the outer mitochondrial membrane (OMM)–based 
protein TSPO (18-kDa translocator protein) (16). This stress-responsive 
protein is up-regulated in many cancers (17–19) and linked to antia-
poptotic activity. Its pharmacological ligands allow its selective tar-
geting to coadjuvate chemotherapy and in vivo tracing of metastatic 
cells (20, 21). Once accumulated on the OMM, TSPO represses mi-
tophagy (22) and deregulates mitochondrial buffering capacity for 
Ca2+ and production of adenosine 5′-triphosphate (ATP) (23) orig-
inated from the oxidative phosphorylation. TSPO recruits and docks 
on mitochondria the A-kinase anchoring protein acyl–coenzyme A 
(CoA) binding domain containing 3 (ACBD3) and protein kinase A 
(PKA) (23, 24), which complexes with the nucleus via the A-kinase- 
anchoring protein AKAP95 (A-kinase-anchoring protein 95) (25, 26). 
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Breast cancer, in which TSPO is overexpressed (27, 28), has modified 
signaling (29) and metabolism (30) of cholesterol, which is trafficked 
by TSPO to fuel the synthesis of pregnenolone (29, 31) within the 
mitochondrial matrix (32). Cholesterol, its intermediates, and their 
enzymatic catalysts such as the aromatase enzyme CYP19A1 are in-
volved in the oncogenic reprogramming (33, 34). All of which make 
TSPO an ideal means to insight the interplay between organelle 
morphology and lipid metabolism in the MRR.
Using cellular and ultrastructural means of analysis combined 
with advanced protocols of imaging, we show that TSPO is required 
to establish contact sites between mitochondria and nucleus during 
MRR, allowing for redistribution of cholesterol that deacetylates 
NF-B, completing the prosurvival response. A novel regulatory 
axis in the MRR that operates via the (i) formation of contact sites 
(ii) and redistribution of cholesterol between mitochondria and nu-
cleus is therefore outlined. This evidence advances our understand-
ing of a key process in mammalian pathophysiology and details a 
physical and metabolic coupling between mitochondria and nucle-
us that is previously unknown.
RESULTS
TSPO facilitates the stabilization of NF-B into the nucleus 
during MRR
The first step of our analysis consisted in assessing the correlation 
between the candidate protein TSPO and the nuclear translocation 
of the prosurvival transcriptional factor NF-B (35, 36), which is an 
acknowledged driving pathway of the MRR. We inspected primary 
human samples of mammary gland tumors, reporting a positive as-
sociation between TSPO level, aggressiveness of lesions (Fig. 1, A 
and B), and NF-B level into the nucleus (Fig. 1, C and D). In line 
with this, transcriptomic analysis of >600 samples of patients with 
breast cancer in The Cancer Genome Atlas (TCGA) showed that higher 
levels of active NF-B are correlated with increased TSPO expres-
sion in the more aggressive forms of breast cancer (HER positive and 
basal types) (Fig. 1, E and F). This is independent of mutations in 
TSPO, whose increased expression is an underlying feature in the neo-
plasia of the mammary gland retained across species (fig. S1, A to E).
To elucidate the nature of this oncogenic interplay between TSPO 
and NF-B, we moved the analysis in vitro and compared two epi-
thelial human breast cancer cell lines, MCF-7, which features low 
TSPO levels, and the more aggressive MDA-MB-231 (henceforth 
referred to as MDA), which instead expresses high TSPO (29) levels 
(Fig. 1, G and H). To engage the MRR, we used the mitochondrial 
stressor staurosporine (STS), which induces the remodeling of mi-
tochondria around the nucleus (as shown in MDA; Fig. 1, J and K) 
and, by promoting TSPO expression (fig. S1, F and G), facilitates the 
nuclear accumulation of NF-B (Fig. 1, L to N). The involvement of 
TSPO in this pathway was confirmed by the failure of STS to induce 
NF-B retro-translocation in MDA cells transiently knocked down 
for TSPO (−TSPO). The outcome of the increased NF-B retro- 
translocation was corroborated by analyses of the transcriptional 
profile of the NF-B–regulated prosurvival genes c-FLIP and Bcl-2 
(Fig. 1, Q to S). Immunocytochemical analysis further highlighted 
the degree of nuclear residency of NF-B upon STS treatment and 
how pruning of the mitochondrial network via pharmacological 
activation of mitophagy by the p62/SQSTM1-mediated mitophagy 
inducer (PMI) (37, 38) reduces the degree of NF-B translocation 
(Fig. 1, O and P). By reducing the size of the mitochondrial network, 
PMI limits the cytosolic space occupancy by mitochondria (fig. S1J) 
and sensitizes human, feline, and canine breast cancer cells to 
STS-induced apoptosis (fig. S1, K to M). The integrity of the mito-
chondrial network, which is reflected by TSPO overexpression and 
accumulation on the OMM, is therefore pivotal to stabilize the retro- 
translocation and transcriptomic capacity of NF-B during MRR 
activation.
Targeting TSPO and its cholesterol binding capacity dictates 
programmed cell death
Like PMI, treatment of MDA cells with the TSPO ligand PK11195 
(Table 1), which competes with the cholesterol binding domains of 
the protein (39), inhibits NF-B retro-translocation (Fig. 2, A and B). 
Equally efficient in this is the cholesterol synthesis inhibitor pravas-
tatin (PVS) (Fig. 2C). This implies the existence of a regulatory 
hierarchy between TSPO, cholesterol, and NF-B in regulating MRR- 
mediated evasion of cell death, which we further assessed by enrolling 
MDA cells stably knocked out for NF-B (NF-B KO) (40). In these 
cells, an additive affect was given by the repression of TSPO concom-
itant with that of NF-B during STS treatment (Fig. 2D). Knocking 
down TSPO (TSPO KD) in MDA cells competent for NF-B was 
thus able to (i) increase sensitivity to apoptosis (Fig. 2E) [an effect 
retained across species (fig. S1, H and I)], (ii) reduce cellular prolifer-
ative capacity (Fig.  2F), and (iii) facilitate the accumulation of the 
proapoptotic protein Bax on mitochondria (Fig. 2, G and H): Last, 
(iv) it also increased the release of cytochrome C (Cyt c) in the cytosol 
(Fig. 2,  I and J). An array of effects acknowledges a role for TSPO 
wider than its interplay with NF-B. In keeping with this, TSPO 
ligands (Table 1) tangibly promoted susceptibility to chemically in-
duced cell death, thereby exacerbating not only STS effects (Fig. 2K) 
but also that of doxorubicin and vincristine (Fig. 2, L and M) in both 
two-dimensional (2D) and 3D cultures (fig. S3A). 
Endocrine therapy resistance up-regulates TSPO, which defines 
the juxtaposition of mitochondria with the nucleus
MCF-7 cells, which are constitutively low in TSPO expression, gained 
resistance to STS-induced apoptosis when wild-type TSPO (WT 
TSPO) was expressed (Fig. 3B). Although, the mutant clone of 
the protein, devoid of the CRAC cholesterol binding domain 
(TSPO∆CRAC), failed to protect from the treatment (Fig. 3, A and B). 
This evidence further argued that the cholesterol-binding capacity of 
TSPO is crucial to drive resistance against chemically induced cell 
death. In keeping with this, TSPO level of expression increases in 
MCF-7 cells that have developed resistance to tamoxifen (MCF7T) 
(6), or in which cholesterol biosynthesis sparked following long-term 
estrogen deprivation (MCF7-LTED) (Fig. 3, D and E) (6, 34, 35).
Treatment with the TSPO ligand FGIN-127 (hereafter referred 
to as FGIN) impairs handling of cholesterol by the protein-like 
PK11195 (Table 1), thereby operating as potential chemical deter-
rent for the nuclear accumulation of the estrogen receptor  (ER). 
The nuclear internalization of the latter is key for the transition of 
epithelial breast tumor toward a more aggressive phenotype, lead-
ing to therapeutic failure of tamoxifen (41, 42) treatment. FGIN 
increases susceptibility to STS-induced cell death (Fig. 3F) as well as 
reduces ER association with the nucleus (fig. S3, D and E). In line 
with these observations, big-data analysis revealed that TSPO is 
overexpressed in cohorts of relapsed patients with breast cancer, in 
which endocrine therapy (ET) was no longer effective and choles-
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Fig. 1. TSPO-rich mitochondria gather on the nucleus during apoptotic treatment and dictate the degree of NF-B retro-translocation. Immunohistochemical analyses 
of human mammary cancer tissues in (A) show the positive correlation between TSPO and lesions’ aggressiveness quantified in (B) (healthy: 8.18 ± 2.4; benign: 24.54 ± 5.2; 
malignant: 40.31 ± 2.7; n = 10). In (C), the same sections are stained for NF-B (yellow), which shows a nuclear pattern according to increased TSPO expression; the plot in 
(D) quantifies the accumulation (healthy: 43.288 ± 10.6; benign: 54.17 ± 12.7; malignant: 75.94 ± 10.7; n = 60). (E and F) Plotted microarray data from The Cancer Genome Atlas 
(TCGA) database on TSPO and NF-B, respectively. (G) The immunofluorescence of MCF-7 and MDA assesses the TSPO level confirmed further by the Western blot in (H) quan-
tified in (I) (5.40 ± 1.49, n = 4). (J) Confocal shot of the mitochondrial network remodeling in staurosporine (STS)–treated MDA cells (immunostained for VDAC and TSPO). 
(K) Three-dimensional reconstruction of remodeled mitochondria. (l) Western blot analysis of NF-B in the cytosol and nucleus of wild-type (WT) and −TSPO MDA cells treated 
or untreated with STS. The relative densitometric evaluation is reported in (M) (control: 1; STS: 0.93 ± 0.79; −TSPO: 1.19 ± 0.89; −TSPO + STS: 0.84 ± 0.56; n = 3) and (N) (control: 1; 
STS: 2.57 ± 1.55; −TSPO: 0.193 ± 0.062; −TSPO + STS: 0.43 ± 0.27; n = 3). The immunostaining of NF-B and mitochondria in STS-treated MDA cells with and without mitophagy 
inducer (PMI) is reported in (O); the quantification in (P) highlights the significant reduction in NF-B translocation when STS is combined with PMI (control: 18.42 ± 4.17; 
PMI: 41.39 ± 9.09; STS: 18.57 ± 4.7; PMI + STS: 30.08 ± 7.8; n = 30). The quantified quantitative polymerase chain reaction assessment of Bcl-2 and c-FLIP mRNA in control 
and −TSPO MDA cells is featured in (Q) and (R) (Bcl-2, control: 1; STS: 1.50 ± 0.065; −TSPO: 0.68 ± 0.02; −TSPO + STS: 0.9 ± 0.04; n = 3; c-FLIP, control: 1; STS 1.5 ± 0.04; −TSPO: 
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Ultrastructural imaging analysis of MCF-7 cells via transmission 
electron micrography (TEM) pictured the disrupted cristae and 
reduced mitochondrial-nuclear distance (passing from ~120 to 
almost ~50 nm in response to STS) (Fig. 3, G and H). This obser-
vation prompted us to investigate the mechanisms dictating such 
a relevant gain in space between mitochondria and nucleus during 
apoptosis.
Mitophagy-evading mitochondria, rich in TSPO, form 
contact sites with the nucleus during MRR
In MCF-7 and MDA cells, mitochondria and nuclear envelope were 
stained for TSPO and Lamin B, respectively. This analysis showed 
that in MDA cells, infiltrates of TSPO in the perinuclear region estab-
lish a constitutive space occupancy by mitochondria, which is indic-
ative of physical interaction (Fig. 4, A and B). This interconnection 
Table 1. List of the chemical structures of the compounds used in the study.  
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Fig. 2. Molecular and pharmacological modulation of TSPO dictate the degree of NF-B retro-translocation and mitochondrial commitment to apoptosis. 
(A) Immunocytochemical analysis of nuclear NF-B (cyan) in MDA cells untreated or treated with STS in the absence or presence of the TSPO ligand PK11195. NF-B signal is 
quantified in (B) (control: 26.86 ± 15.02; PK11195: 21.26 ± 12.24; STS: 49.36 ± 23.52; PK11195 + STS: 34.52 ± 21.36; n = 15), and (C) reports the evaluation of nuclear NF-B 
signal following STS treatment in combination with pravastatin (PVS) (control: 25.14 ± 14.78; PVS: 25.70 ± 17.88; STS: 36.20 ± 26.64; PVS + STS: 32.59 ± 21.00; n = 10). Histo-
gram in (D) quantifies the cell death in MDA cells controlled and stably knocked out for NF-B exposed to STS (NF-B KO: 1.3 ± 0.69; NF-B KO + STS: 38.18 ± 4.04; −TSPO/
NF-B KO: 2.88 ± 0.07; −TSPO/NF-B KO + STS: 37.1 ± 3.45; n = 3), while (E) refers to the TUNEL (terminal deoxynucleotidyl transferase–mediated deoxyuridine triphos-
phate nick end labeling) assay in control and −TSPO MDA cells exposed to STS (control: 1.37 ± .27; STS: 47.38 ± 2.74; −TSPO: 7.19 ± 0.85; −TSPO + STS: 61.25 ± 2.06; n = 3). 
(F) Recording of the proliferation assay in the same cells. The Western blot in (G) shows the higher degree of Bax accumulation in mitochondrial fractions of −TSPO MDA 
cells following STS treatment quantified in the plot of (H) (control: 1; STS: 1.2 ± 0.18; −TSPO: 2.3 ± 0.27; −TSPO + STS: 3.1 ± .048; n = 3). The Western blot in (I) is the analysis 
of Cyt c levels in the cytosolic portion, and (J) is its quantification (control: 1; control + STS 1.82 ± .06; −TSPO: 1.27 ± 0.03; −TSPO + STS: 2.79 ± 0.18; n = 3). The exacerbation 
of STS-induced cell death by TSPO ligands PK11195, FGIN, and Ro-5 is reported in (K), (control: 3.71 ± 0.94; STS: 49.98 ± 0.84; STS + PK11195: 59.43 ± 0.68; STS + FGIN: 
62.41 ± 1.4; STS + Ro-5: 62.16 ± 1.57; n = 3). Ligands that coadjuvate also doxorubicin-induced cell death (L) (control: 5.9 ± 1.52; doxorubicin: 16.00 ± 2.63; doxorubicin + 
PK11195: 32.7 ± 7.03; doxorubicin + FGIN: 38.9 ± 2.3; doxorubicin + Ro-5: 36.1 ± 2.23; n = 4) and vincristine (M) (control: 10.05 ± 0.95; vincristine: 15.61 ± 0.67; vincristine + 
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Fig. 3. Cholesterol-binding capacity is pivotal for TSPO-mediated prevention of programmed cellular demise and mitochondrial associated with the nucleus. 
The domain model in (A) refers to the WT TSPO and TSPO∆CRAC constructs expressed into MCF-7 cells whose degree of STS-induced cell death was quantified at 16-hour 
treatment (B) (control: 29.86 ± 8.48; +TSPO: 15.37 ± 4.6; +TSPO∆CRAC: 2.21; n = 5) at the time expression of plasmids was maximal: 48 hours as shown in (C). The long-term 
estrogen-deprived (LTED) MCF-7 cells, which are more resistant to cell death, express higher level of TSPO, which is enhanced further by tamoxifen (D). The significant 
differences in TSPO accumulation with and without tamoxifen are quantified in (E) (MCF-7 control: 1; MCF-7 + TAM: 19.85 ± 9.8; LTED control: 45.88 ± 13.3; LTED + TAM: 
76.41 ± 11.3; n = 3). (F) Cell death analysis in the same cells showing that MCF7T cells are resistant to STS in comparison to control MCF-7 (MCF-7 control: 8.09 ± 4.68, 
MCF7T control: 7.17 ± 3.34, MCF-7 + FGIN: 11.65 ± 4.22, MCFT + FGIN: 17.33 ± 14.58, MCF-7 + STS: 61.61 ± 47.89, MCF7T + STS: 34.38 ± 33.31, MCF-7 + FGIN + STS: 
64.56 ± 44.49, MCF7T + FGIN + STS: 41.11 ± 39.71; n = 3). The transmission electron micrography (TEM) presented in (G) shows the remodeling of the mitochondrial net-
work (M; yellow) toward the nucleus (N; blue) in STS-treated MCF-7 cells. The quantification reported in (H) indicates the gain in distance (greater than 50 nm) between 
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Fig. 4. Nucleus-associated mitochondria (NAM) form during induction of MRR, for which the inhibition of mitophagy is required. The immunocytochemical analyses in 
(A) investigate the proximity of the mitochondrial network to the nucleus in MCF-7 and MDA cells with relative quantification in (B) (MCF-7: 1 ± 0.9; MDA cells: 5.40 ± 1.5; n = 3). The 
Western blot in (C) shows the redistribution of TSPO in the nucleus following treatment with STS and rotenone (ROT) with densitometry reported in (D) (TSPO:-actin ratio in 
the cytosol, control: 1; STS: 0.89 ± 0.54; ROT: 0.905 ± 0.48; n = 3; TSPO:lamin B1 ratio in the perinucleus, control: 1; STS: 1.81 ± 1.16; ROT: 2.03 ± 1.13; n = 3; TSPO:histone H3 ratio in the 
nuclear core, control: 1; STS: 5.60 ± 3.70; ROT: 2.62 ± 1.08; n = 3). (E) TEM micrographs of dimethyl sulfoxide (control) and STS-treated MDA cells confirm the physical interaction 
between mitochondria (M; yellow) and the nucleus (N; blue). (F) Quantification of the distance between mitochondria and the nucleus in control and STS-treated MDA cells (con-
trol: 65.45 ± 13.89 nm; STS: 21.75 ± 1.19 nm; n = 15). (G) Kinetics of dihydroethidium (DHE)–based measurement of ROS production in control and −TSPO MDA cells. The quantifi-
cation in (H) confirms the lower cytoplasmic ROS in −TSPO cells (control: 1; −TSPO: 0.59 ± 0.07; n = 20). The average mitochondrial accumulation of the DHE derivative MitoSox 
(I) reports significantly low ROS levels in −TSPO MDA cells (control: 1; −TSPO: 0.73 ± 0.04; n = 20). (J) Confocal imaging of MDA cells exposed to STS, PMI, or STS + PMI: The latter 
prevents remodeling of the mitochondrial network on the nucleus (n = 5). The box plot in (K) reports the quantification of infiltrates per cell (STS: 16.17 ± 11.17; STS + PMI: 10.67 ± 6.98 m; 
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increases in response to STS, as detailed by both immunoblotting of 
subcellular fractions (Fig. 4, C and D) and TEM analyses (fig. S2, A 
and B). TSPO, in response to STS, was observed to be present in the 
portion of the cytosol occupied by mitochondria as well as in the 
nuclear envelope and its core (Fig. 4, C and D). A similar dynamic 
redistribution of mitochondria (read by the accumulation of TSPO) 
is obtainable also by the mitotoxin rotenone (ROT) (43), which in-
duces MRR (Fig. 4, C and D).
The ultrastructural analysis also revealed the prominent interor-
ganellar coupling that generated an all-encompassing structure in 
and around the nucleus, which we called the nucleus-associated mi-
tochondria (NAM). Means of quantification revealed the formation 
of actual contact sites with a statistical reduction in distance-space 
between mitochondria and nucleus below 30  nm and observable 
membrane fusion (Fig. 4, E and F).
The mitochondrial remodeling could therefore crucially influence 
the signaling of diffusible molecules such as ROS, which are ac-
knowledged factors in the retrograde response (1, 14) and dependent 
on their tonicity by the level of TSPO (16). In line with this, both 
cytoplasmic and mitochondrial ROS levels decrease when TSPO is 
down-regulated (Fig. 4, G to I). The NAM-induced change in space- 
distance would therefore favor the diffusion capacity of ROS, maximizing 
their impact on perinuclear and nuclear regions. Notably, the remod-
eling of mitochondria on the nucleus, alike the retro-translocation 
of NF-B, is limited by the mitophagy-driven trimming of the network, 
here induced by PMI (Fig. 4, J and K) (31). The formation of NAM 
was further corroborated by assessing the level of lamin B in purified 
mitochondrial fractions of cells exposed to STS treatment (Fig. 4l).
A TSPO-mediated molecular complex (TSPO-ACDB3-PKA-
AKAP95) tethers mitochondria to the nucleus
NAM form also in the mouse embryonic fibroblasts (MEFs), in 
which the expression level of TSPO is equally critical as in cancer 
cells to establish mitonuclear contacts (Fig. 5, C to F). “Variance” 
filter applied to confocal Airyscan images with immunofluorescence 
[lamin B1–ATP synthase (ATPB)] convincingly detail how the down- 
regulation of TSPO (−TSPO) in MDA cells releases mitochondria from 
the nucleus, while its overexpression (+TSPO) in MEFs results in the 
coalescing of the mitochondrial network with the nuclear envelope 
(Fig. 5, A to D). These observations were corroborated at ultrastruc-
tural level via TEM analysis, which unequivocally showed the forma-
tion of contacts between mitochondria and the nucleus in the face of 
increased TSPO expression (Fig. 5, E and F). TSPO-overexpressing 
MEFs (which feature accumulated NF-B in their nucleus) gained 
significant resistance to STS-induced cell death, which was otherwise 
lost when the TSPO-CRAC mutant clone of the protein (unable to 
bind cholesterol) was expressed (Fig. 5G).
We then attempted to dissect the mechanisms by which TSPO 
could mediate such a tethering role between mitochondria and the 
nucleus, hypothesizing a partnering activity with other molecules. 
Bioinformatic analysis outlined the TSPO interactors (Fig. 5H), and 
among these, we teased out those with established anchoring capac-
ity and capable of an alternative intracellular location from the mi-
tochondria. From the analysis, ACBD3, which is a multifunctional 
interactor of TSPO and PKA (23, 24), emerged as a main candidate. 
Considering that PKA, under stress, is recruited on the nucleus and 
anchored via AKAP95 (25, 26), we therefore hypothesized the for-
mation of a multiprotein complex formed by TSPO, ACBD3, PKA, 
and AKAP95, which tethers mitochondria to the nucleus (Fig. 5I). 
This is far more evident under STS-induced stress, when PKA pools 
on the nucleus increase in MDA cells (Fig. 5, J to L). To further 
corroborate this hypothesis, we employed coimmunoprecipitation 
analyses to determine whether TSPO and AKAP95 interact. When the 
expression of TSPO is high, as in the MDA, the interaction with AKAP95 
is evident and ACBD3 is mediated (Fig. 5, M and N). Knocking down 
ACBD3 (−ACBD3) (transfection efficiency shown in fig. S4J) is in-
stead sufficient to impair this interaction, thereby reducing the as-
sociation between mitochondria and the nucleus (fig. S5, A and B).
The distinctive molecular nature of NAM from the mitochondria- 
associated ER membranes (MAM) was also proven by assessing 
their level in cells devoid of the integral membrane protein VAPB5 
and mitofusin 2 (44), whose removal did not affect the connection 
between mitochondria and the nucleus (figs. S4, F and G, and S5, 
C and D).
NAM exploit TSPO to redistribute cholesterol into 
the nucleus and promote NF-B–mediated transcription 
of genes
Oxidized forms of cholesterol as demonstrated by the use of the ox-
ysterol 7-ketocholesterol (7-KC) (45, 46) promote the accumulation 
of NF-B, and subsequently the formation of NAM (Fig. 6, A to E).
Notably, this treatment modifies the pattern of TSPO expression 
too as well as that of other components of the steroidogenic protein 
complex transduceome (19): the oxysterol receptor liver X receptor 
 (fig. S2, F and G) (47), the ATPase (adenosine triphosphatase) family 
AAA domain-containing protein 3 (ATAD3) (fig. S2, H and I), and 
the steroidogenic acute regulatory protein (STAR) (fig. S2, H and J). 
This, in turn, suggests a mechanistic interplay between the mitochondrial 
handling of cholesterol, its metabolism, and MRR. Even though other 
lipids may be involved in this route of communication, we detailed 
the redistribution of cholesterol after remodeling of the mitochon-
drial network during MRR. In MDA cells expressing the red variant 
of the green fluorescent protein (mt-RFP), we imaged the pools of 
cholesterol via the fluorescent compound filipin, which depicted the 
localization of the lipid into foci close to and around the nucleus: 
foci that disappeared in −TSPO MDA cells (Fig. 6, F and G).
The STS-induced retro-trafficking of cholesterol was confirmed 
by imaging the lipid enrichment of the nuclear membranes in MDA 
cells with the fluorescent probe Di-4-ANEPPDHQ (Fig. 6, H and I). 
In the same conditions, the efflux of cholesterol from the nucleus 
could be observed during cell treatment with TSPO ligands (Fig. 6J), 
as well its marked influx when the protein is overexpressed (Fig. 6K). 
The pattern of cholesterol was also assessed by live imaging using 
dehydroergosterol [ergosta-5,7,9(11),22-tetraen-3-ol, DHE] (48), 
which showed the inhibition of this nuclear redistribution of the lipid 
when cells are cotreated with the TSPO ligand PK11195 (49) or the 
intracellular cholesterol transport inhibitor U1866A (Fig. 6, L and M). 
Most notably, the pharmacological targeting of TSPO with PK11195 
did also prevent remodeling of mitochondria (Fig. 6, N and O).
The interdependence between cholesterol accumulation in the 
nucleus and transcriptional activity of NF-B was also confirmed 
by monitoring the expression levels of the prosurvival genes (c-FLIP 
and Bcl-2), both of which were reduced by the cholesterol synthesis 
inhibitor lovastatin (Fig.  6,  P  and  Q), likewise in −TSPO cells 
(Fig. 1, N and O). Furthermore, we gained evidence of the increased 
levels of NF-B deacetylation, which is indicative of its activation, 
during STS treatment, associated with the reduced nuclear accumula-
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Fig. 5. TSPO is required for the formation of mitonuclear contact sites by forming a multimolecular tethering complex. (A) Processed Airyscan-generated confocal 
images of colocalization between the nuclear envelope (red) and mitochondria (green) in control and −TSPO MDA cells. The quantification of the overlapping area is plotted 
in the histogram in (B) (control: 0.31 ± 0.21; −TSPO: 0.15 ± 0.03; n = 5). (C) Images [processed as in (A)] refer to control and TSPO-overexpressing MEFs quantified in (D) (control: 
0.16 ± 0.04; +TSPO: 0.22 ± 0.14, n = 3). Representative TEM micrographs of control and TSPO-overexpressing MEFs are shown in (E): Mitochondria are highlighted in yellow (M) 
and nucleus in blue (N). Quantification of minimum distance between mitochondria and the nucleus is presented in (F) (n = 1). The bar chart in (G) summarizes the cell death 
assay in MEFs (WT), overexpressing WT TSPO (+TSPO) or expressing TSPO∆CRAC (TSPO) following STS treatment (WT: 11.74 ± 10.17%; +TSPO: 71.86 ± 68.55%; TSPO∆CRAC: 
22.24 ± 18.97%; n = 2). The graphical representation in (H) pictures the nuclear and nonnuclear interactors of TSPO used to identify partners aiding the formation of contact 
sites clearly visible via TEM analysis reported in (I). The presence of a specialized tethering structure requires the accumulation in the nucleus of the PKA; see the immunoflu-
orescence in (J) and relative quantification in (K). Confirmation of the kinase redistribution was also obtained (L). The coimmunoprecipitation of AKAP95 and TSPO proteins 
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Fig. 6. Redistribution of cholesterol in the nucleus aids NF-B activity is secondary to NAM formation and requires functional TSPO. Immunostained MDA cells 
incubated with 7-KC show TSPO up-regulation (A) confirmed by protein analyses in (B) and quantified in (C) (control: 94.86 ± 6.5, 7-KC: 136.59 ± 6.76; n = 3). Orthogonal 
projection of the mitochondrial infiltrates in response to 7-KC is pictured in (D) with numbers plotted in (E) (control: 4.22 ± 2.9; 7-KC: 12.34 ± 2.3; n = 9). Confocal images 
of −TSPO MDA cells stained with the cholesterol marker filipin (F) reveal the amount of nuclear accumulation in the conditions plotted in (G) (control: 1.04 ± 0.009; −TSPO: 
0.2 ± 0.001; n = 8). (H) Cholesterol stained with the dye Di-4-ANEPPHQ (ANE), and the plot in (I) reports its accumulation in the nuclear envelope following STS. The bar 
chart in (J) is the analysis of nuclear cholesterol (g/ml) in MDA cells treated with PK11195 and Ro-5 (control: 1; PK11195: 0.86 ± 0.008; Ro-5: 0.54 ± 0.03; n = 3); nuclear 
cholesterol was also quantified in MEFs overexpressing TSPO (+TSPO) or expressing its mutated isoform (TSPO∆) (K). Screen shots in (L) are of the live-cell imaging anal-
ysis of the cholesterol analog ergosta-5,7,9(11),22-tetraen-3-ol in CF35 cells costained with MitoTracker Red with data plotted in (M) (control: 23.629 ± 17.03; PK11195: 
9.78 ± 5.81; U-18666A: 12.16 ± 5.36; n = 25). Confocal images in (N) indicate that PK11195 prevents remodeling of mitochondria as confirmed by the plot of the corre-
sponding skeletonized mitochondrial network in (O) (control: 371.6 ± 2.3; PK11195: 532 ± 12; STS: 275 ± 62.9; PK11195 + STS: 390 ± 86.5; n = 10). (P and Q) Analysis of Bcl-2 
and c-FLIP mRNA levels in cotreatment with STS and lovastatin (Bcl-2, control: 1; STS: 1.08 ± 0.04; vehicle: 0.6 ± 0.18; lovastatin + STS: 0.77 ± 0.2; n = 3; c-FLIP, control: 1; STS: 
1.49 ± 0.32; lovastatin: 0.052 ± 0.1; lovastatin + STS: 0.85 ± 0.10; n = 3). Last, the protein analysis of Sirtuin-1 in the nucleus is reported in (R) and that of NF-B deacetylation 
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event that is favored by the repression of TSPO level (Fig. 6, R and S). 
Depletion of cellular cholesterol via methyl--cyclodextrin mimics 
similar protective effect on deacetylation of the NF-B (Fig. 6T).
The final graphical model in Fig. 7 summarizes the key steps of 
this pathway, in which association of mitochondria with the nucleus 
and redistribution of cholesterol regulate MRR activation and exe-
cution along with alterations in Ca2+ and ROS signaling.
DISCUSSION
In this work, we demonstrate that mitochondria can establish points 
of contact with the nucleus to favor spatially confined biochemical 
events that promote nuclear stabilization of prosurvival transcrip-
tional factors such as NF-B. We called these newly identified contact 
sites NAM. We also report that cholesterol works as an intermediate 
or a facilitator of the mitochondria-to-nucleus retro-communication 
together with ROS and Ca2+, which have been acknowledged as the 
prevalent dynamic signaling molecules between the two organelles 
(1, 2). The accumulation of cholesterol in the nuclear envelope emerges 
as regulator of cellular reprogramming toward stress resistance and 
survival (Fig. 6, F to M). Even though cholesterol is known to affect 
transcription of genes (47), it is here reported to be trafficked into 
hot spots at the interface between mitochondria and the nucleus to 
promote their communication, thus resembling other platforms for 
the exchange of information such as those between the ER and mito-
chondria (ER-MAMs) (52), which we prove to be molecularly distinct 
from the NAM (fig. S5, F and G).
Following mitochondrial reorganization, TSPO may therefore 
deliver its lipid cargo, cholesterol, into the nuclear core of the cell 
where the concurrence of ROS may lead to auto-oxidative products 
of cholesterols (oxysterols) (46). The pattern of elements of the 
transduceome complex (31), which all converge into the nucleus 
along with TSPO, strongly argues for this (fig. S2, E to J). We spec-
ulate that the enrichment of the nuclear envelope with lipids such as 
cholesterol, inducing a change in the physical properties (Fig. 6H), 
represents a crucial step in the altered transcriptional profile that 
enables aggressive cancer cells to differentiate from their less per-
sistent counterparts. Here, we unveiled that cholesterol is pivotal for 
the efficiency of the retrograde response as the degree of NF-B 
acetylation is affected by its redistribution in the nucleus (Fig.  6, 
R to T), which represses the NAD-dependent deacetylase SIRT-1 as 
previously proposed (50, 51).
While the observation that the mitochondrial interactome is 
crucial to cellular health is not new (53), the fine regulation of mito-
chondrial juxtaposition on the nucleus is. We have here detailed 
that TSPO is required for this interorganellar interaction, and, in 
turn, its ligands work as efficient pharmacological modulators of this 
coupling (Fig.  6,  L  and  M). We propose that a pool of proteins 
formed by ACBD3, PKA, and AKAP95 bridge TSPO-positive mito-
chondria and the nucleus: A tether that is visible in the tomograph 
reported in Fig. 5I and fig. S5E. Even though we cannot rule out the 
possibility that a voltage-dependent anion channel (VDAC) is required 
to ensure the right positioning of the OMM and tethering with the 
nucleus, we envisage a relay between stress proteins such as TSPO, 
ACBD3, and PKA (23, 24).
TSPO is an ancient molecule (54), and the part it plays in the 
NAM may be an evolutionary adaptation to bridge the two genomes. 
Clearly, it is exploited in such a scope during pathologies.
NAM are prominent in the aggressive line (MDA) derived from 
advanced lesions of the mammary gland when compared with the 
less aggressive counterpart: the MCF-7. In this cellular model, STS 
treatment is nonetheless able to promote a statistically significant reduc-
tion in the distance between mitochondria and the nucleus (Fig. 3, G and 
H), even though with reduced capacity than in MDA cells (Fig. 4, 
A and B). This steady-state formation of NAM may be an “already 
established” communication platform in these cells, which is exacerbat-
ed by cholesterol dysregulation and likely by the therapeutic protocols.
NAM will, in turn, increase the exposure of the nucleus to hy-
drogen peroxide (H2O2), superoxide (O2−), as well as hydroxyl radical 
(OH−) generated in excess by defective mitochondria overexpress-
ing TSPO. The nucleus is usually out of reach of mitochondrial O2− 
and OH−, which have very low estimated diffusion coefficients (55). 
The formation of NAM would bring mitochondria in a closer range to 
the nuclear DNA, facilitating the exposure of reactive species of the 
oxygen to the nuclear DNA (56), which maximize NF-B activation.
NAM may therefore represent both a defensive mechanism in 
response to apoptotic cues in the short term, as well as a detrimental 
coupling that compromises DNA integrity in the long one, leading 
to genomic alterations. This hypothesis ties well into the observations 
that cytoskeletal reorganization (which we have not here investigated) 
and cellular morphology are key factors in cellular resistance to apop-
tosis as well as in regulating the NF-B signaling (57, 58). Equally, 
nuclear pleomorphism of tumors, proposed as a biomarker of ma-
lignancy for breast cancer (59), and the associated somatic mutations 
Fig. 7. Working model of the formation of contact sites between mitochondria and the nucleus (NAM) during the execution of the MRR. The juxtaposition of mitochon-
drial and nuclear membranes facilitates the convergence of mitochondria-derived signaling molecules to the nucleus, activating prosurvival pathways such as the one con-
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could be the consequence of the continuous exploitation of this 
localized, but nuclear-focused stress signaling.
Mitochondrial repositioning is nonetheless secondary to ineffi-
cient mitochondrial quality control for impaired mitophagy (60), 
which causes the accumulation of malfunctioning organelles and their 
bypassed respiratory products. TSPO suppresses PINK1-PARKIN–
driven mitophagy by preventing the ubiquitination of mitochondrial 
proteins (16). TSPO-rich mitochondria are therefore prone to repo-
sitioning on the nucleus, as they can systematically evade control by 
autophagy. The previously described deubiquitinating properties of 
TSPO (16) lead us to speculate that trafficking of TSPO onto the 
nuclear envelope could replicate a similar outcome in the nucleus 
by preventing nucleophagy (61) causing the undulated nuclear en-
velope observed ultrastructurally (fig. S2A). The alteration in lipid 
composition of the membranes to which TSPO localizes (mitochon-
dria) or relocalizes (nucleus) could also be instrumental for 
this as well as to the altered organellar life cycle and protein inter-
actome (Fig. 5H). Mitochondrial network remodeling, cholesterol 
sequestration on the perinuclear region, and cell death evasion are 
avoidable by the down-regulation of TSPO, its pharmacological 
inhibition, as well as the pharmacological activation of mitophagy. 
Furthermore, TSPO is overexpressed in mammary gland cell lines 
that have developed resistance to ET, thus conferring resistance to 
those who might instead be susceptible to the treatment (Fig. 4, 
D to G). Overexpression of the TSPO-CRAC mutant, which fails 
binding of cholesterol by TSPO, is unable to replicate the same 
effect (Fig. 5G). These experiments propose cholesterol as an on-
cometabolite in the resistance primed by MRR, which is executed 




Immunofluorescence: Cells were fixed in 4% paraformaldehyde 
(PFA) [10 min, room temperature (RT)] followed by three 5-min 
washes in phosphate-buffered saline (PBS). Permeabilization was 
performed with 0.5% Triton-X in PBS (10 min at RT) followed by 
washing. Blocking was carried out for 1 hour at RT in 10% goat 
serum and 3% bovine serum albumin in PBS. Primary antibody 
incubations were conducted overnight for 16 hours at 4°C in blocking 
solution as described. After a further wash step, secondary antibodies 
were incubated for 1 hour in blocking solution, before a final wash 
step. Cells were then mounted on slides with 4′,6-diamidino-2- 
phenylindole (DAPI) mounting medium (Abcam, ab104139). Cells 
were stained with the following primary antibodies: ATPB (1:400; 
Abcam, ab14730); lamin B2 (1:500; Abcam, ab8983); TSPO (1:200; 
Abcam, ab109497), NF-B (1:500; Abcam, ab16502); ATAD3 
(1:1000; gift from I. Holt, Biodonista), LXR (1:400; Abcam, ab28479), and 
STAR (1:500; Abcam, ab58013), and the following secondary anti-
bodies: -mouse Alexa 555 (1:1000; Life Technologies, A21424) and 
-rabbit Alexa 488 (1:1000; Life Technologies, A11008).
Single dye immunofluorescence was used to stain paraffin sec-
tions of human mammary tissues with different TSPO antibody 
(ab109497)/NF-B (ab32360). The binding of mouse primary anti-
bodies was detected using Alexa Fluor 488 (or 594) fluorochrome- 
conjugated goat anti-mouse IgG (immunoglobulin G). Tissue 
sections were mounted with Fluoroshield Mounting Medium with 
DAPI to show.
Cell culture
MDA-MB-231 and MCF-7 human breast cancer cell lines, CF41 
canine mammary line, K248P feline mammary line, WT, and Mito-
fusin 2−/− cell lines were all maintained at 37°C under humidified condi-
tions and 5% CO2 and grown in Dulbecco’s modified Eagle’s medium 
(Life Technologies, 41966-052) supplemented with 10% fetal bovine serum 
(Life Technologies, 10082-147), penicillin (100 U/ml), and strepto-
mycin (100 mg/ml) (Life Technologies, 15140-122). K248P cells were 
additionally supplemented with insulin (10 g/ml) (Sigma-Aldrich). 
Cells were transiently transfected with genes of interest or small 
interfering RNA as described previously (13, 15) or using the 
manufacturer’s instructions for Lipofectamine 3000 (Thermo Fisher 
Scientific, 18324010). Mnf2KO MEFs were generously provided by 
Prof. L. Scorrano (University of Padua, Italy).
Cell fractionation
Cells were lysed in cold isotonic buffer [250 mM sucrose, 10 mM KCl, 
1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 20 mM Hepes, (pH 7.4)] 
containing protease inhibitor cocktail (Roche, 05892791001) by pass-
ing through a 26-gauge needle 10 times using a 1-ml syringe, followed 
by 20-min incubation on ice. Nuclei were separated by centrifugation 
at 800g for 5 min at 4°C. For nuclear fractions, pellets were washed 
once in isotonic buffer followed by centrifugation 800g for 10 min at 
4°C. Pellets were suspended in standard lysis buffer [150 mM NaCl, 
1% v/v Triton X-100, 20 mM tris (pH 7.4)] plus 10% glycerol and 
0.1% SDS and sonicated for 5 s to dissolve pellet. For mitochondrial 
fractions, supernatants were transferred to fresh tubes and centrifuged 
at 10,000g for 10 min at 4°C. Subsequent supernatants were collected as 
the cytosolic fractions, while mitochondrial pellets were washed once 
in cold isotonic buffer and then centrifuged at 10,000g for 10 min at 
4°C. Last, mitochondrial pellets were lysed in lysis for 30 min on ice.
Western blot
Sample proteins were quantified using a BCA Protein Assay Kit 
(Thermo Fisher Scientific, 13276818). Equal amounts of protein (10 to 
30 g for whole-cell lysates/cytosolic fractions; 10 g for mitochondrial 
nuclear fractions) were resolved on 12% SDS–polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose membranes (Thermo Fisher 
Scientific, 10339574). The membranes were blocked in 3% nonfat dry 
milk in TBST [50 mM tris, 150 mM NaCl, 0.05% Tween 20, (pH 7.5)] 
for 1 hour and then incubated with the appropriate diluted primary 
antibody at 4°C overnight: LC3 (1:1000; Abcam, ab48394), TSPO (1:5000; 
Abcam, ab109497), actin (1:2000; ab8266), ATPB (1:5000; Abcam, 
ab14730), BAX (1:1000; Abcam, ab32503), Cyt c (1:1000; ab13575), 
histone H3 (1:1000; ab8580), NF-B (1:1000; ab32360), acNF-B 
(1:500; ab19870), SIRT-1 (1:1000; ab110304), lamin B1 (1:1000; 
ab16048), and MTCO1 (1:1000; ab14705). Membranes were washed 
in TBST (3 × 15 min at RT) and then incubated with corresponding 
peroxidase-conjugated secondary antibodies (Dako, P0447, P0448) 
for 1 hour at RT. After further washing in TBST, blots were developed 
using an ECL Plus on Western Blotting Detection Kit (Thermo Fisher 
Scientific, 12316992). Immunoreactive bands were analyzed by per-
forming densitometry with ImageJ software.
Confocal imaging/ImageJ
Fluorescence labeling was observed through an LSM 5 Pascal con-
focal microscope (Zeiss, Oberkochen, Germany), and images were 
recorded with the Pascal software (Zeiss). All image analyses were 
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All staining was checked for nonspecific antibody labeling using con-
trol samples without primary antibody. None of the controls showed 
any signs of nonspecific fluorescence. For immunocytochemistry 
(ICC) and immunohistochemistry (IHC) imaging, single optical sec-
tions were analyzed. The infiltrate analysis was done using orthogonal 
rendering 3D optical stacks and counting the number of infiltrates 
per cell nucleus. The mitochondrial network analysis was performed 
using the “skeletonize” plug-in. Higher-resolution Airyscan processed 
images were acquired using an LSM 880 confocal with Airyscan (Carl 
Zeiss, Jena, Germany) system with GaAsP detectors and a module 
for Airyscan imaging. In Airyscan modes, a 63× Plan Apochromat (1.4 
NA) oil objective was used. Confocal imaging was sequential for dif-
ferent fluorophore channels to obtain a series of axial images. Imag-
es of cells were optimized for visualization by manually adjusting the 
minimum and maximum intensity values of the histogram in the Zen 
software (Carl Zeiss). Images were analyzed using the variance filter 
and quantified by colocalization of fluorophores.
Cell proliferation assays
Cell proliferation assays were performed using the WST-1 Cell Pro-
liferation Assay Kit (ab65473) and assessed on a standard plate reader 
(Tecan Sunrise).
Cell death assays
Cells were fixed in 4% PFA for 10 min at RT followed by three 5-min 
washes in PBS. Permeabilization was performed with 0.2% Triton X-100 
in PBS for 10 min at RT followed by washing. To assess apoptosis- 
associated DNA fragmentation, a TUNEL Assay Kit (ab66108) was 
used according to instructions by the manufacturer. Alternatively, cells 
were live stained with Hoechst 33342 (Sigma-Aldrich, H6024) and 
propidium iodide (Sigma-Aldrich, 25535) to mark apoptotic cells and 
imaged on an inverted fluorescence microscope.
Fluorescence imaging
Cells were incubated with 5 M dihydroethidium (DHE; Life Tech-
nologies, D-1168) or 5 M MitoSOX (Life Technologies, M-36008) 
in recording media [125 mM NaCl, 5 mM KCl, 1 mM NaH2PO4, 20 mM 
Hepes, 5.5 mM glucose, 5 mM NaHCO3, and 1 mM CaCl2, (pH 7.4)] 
for 30 min at 37°C. Cells were washed once in recording medium 
and then transferred to a Leica SP-5 confocal microscope (63× oil 
objective lens) for imaging, and fluorescence intensity was measured 
through continuous recording for at least 10 min. Settings were kept 
constant between experiments. Mitochondrial regions of interest were 
selected, and the corresponding fluorescence intensities were calculated. 
For assay of cholesterol transport, Ergosta (dehydroergosterol- ergosta-
5,7,9(11),22-tetraen-3-ol) was prepared and loaded as previously 
described (62). Briefly, Ergosta was added to an aqueous solution 
of MCD (3 mM Ergosta and 30 mM MCD). This mixture was 
overlaid with nitrogen, continuously vortexed under light protec-
tion for 24 hours at RT, and filtered through a 0.2-m filter to re-
move insoluble material and Ergosta crystals. Then, 20 g of DHE 
was added to the cells in the form of DHE-MCD complexes and allowed 
to incubate for 90 min at RT in PBS. Before imaging, cells were washed 
three times with culture media before being incubated with 20 nM 
MitoTracker Red CMXRos. Cells were washed and then imaged.
Statistical analysis
Data are presented as means ± SD of the mean. One-way analysis of 
variance (ANOVA) was used in multiple-group comparisons with 
Bonferroni’s post hoc test to compare two datasets within the group, 
and P < 0.05 was considered significant. All analyses were per-
formed in Microsoft Office Excel 2010 and GraphPad Prism 7. *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001.
Preparation of cells for electron microscopy (TEM 
and Immunogold TEM)
For TEM analysis, MDA-MB-231 cells (control and treated with 
0.5 M for 16 hours) were fixed at RT with 2.5% glutaraldehyde (v/v) 
in 0.1 M sodium cacodylate buffer (pH 7.4) for 3 hours. The cells 
were pelleted by centrifugation, washed in buffer, and postfixed 
for 1 hour with 1% osmium tetroxide in 0.1 M sodium cacodylate 
buffer. Samples were thoroughly rinsed, dehydrated in a graded series 
of ethanol, and embedded in epoxy resin (TAAB 812). Ultrathin 
sections (70 to 90 nm) were cut using a Leica UC7 ultramicrotome 
mounted on 150 mesh copper grids and contrasted using UranyL-
ess (TAAB) and 3% Reynolds lead citrate (TAAB). Sections were 
examined at 120 kV on a JEOL JEM-1400Plus TEM fitted with a 
RUBY digital camera (2kx2k). For TEM immunogold labeling, cell 
samples were fixed with 4% (w/v) PFA, 0.1% (v/v) glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4) for 4 hours at RT, and spun down 
on 20% gelatine. Gelatine cell pellets were cryoprotected by incubating 
in 2.3 M sucrose overnight at 4°C. Gelatine blocks containing cells 
were cut further into 1- to 2-mm cubes, mounted on aluminum pins, 
and cryofixed by plunging into liquid nitrogen. Samples were stored 
in liquid nitrogen before cryosectioning. Ultrathin sections (70- to 
90-nm thick) were cut using a Leica EM FC6 cryo-ultramicrotome 
and mounted on Pioloform film–supported nickel grids according 
to the Tokuyasu method. Sections were immunolabeled using an-
ti-TSPO (1:200) (Abcam, ab109497) followed by a 12-nm colloidal 
gold anti-rabbit secondary antibody (1:40) (Jackson ImmunoResearch). 
Grids were examined at 120 kV on a JEOL JEM-1400Plus TEM fitted 
with a RUBY digital camera (2kx2k).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/51/eabc9955/DC1
View/request a protocol for this paper from Bio-protocol.
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